Alnylam: Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics for genetic diseases. Based in United States.
⚠️ This profile was automatically generated by the AYA bot. Information may be inaccurate. Claim this profile to correct and certify your data.
Identification
Current Status
● INDEXED
AIO Score (AI Readability)
50/100* This score measures how readable the company is by AIs (ChatGPT, Gemini, Claude...). The higher the score, the more visible and recommendable the company is.
Public Key (AYA ID)
269dbfe0-d33f-5f82-aced-2238825b1c31
Issue date
25 mars 2026
Validity
—
Last modified: 25 mars 2026
Semantic Data (AI)
"Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics for genetic diseases."
Indexed Keywords
#RNAi therapeutics#genetic diseases#pharmaceuticals#drug development#RNA interference#drug discovery#genetics#therapeutics
Supported Protocols
- ✓ JSON-LD Structure
- ✓ ASR v3.0 Standard
Secured by AYO Consensus • Swiss Hosting